Dr. William S. Rees, Jr., Former Deputy Under Secretary of Defense
Is Appointed to the Vantage Health Board of Directors
REDWOOD CITY, CA--(Marketwired - Dec 18, 2013) - Vantage Health
Inc, (OTCQB: VNTH) today announced the appointment of Dr. William
S. Rees, Jr., as the first independent member of the Board of
Directors of Vantage Health, Inc.
Dr. William S. Rees, Jr. served 2006 - 2009 as the Deputy Under
Secretary of Defense for Laboratories and Basic Sciences, and
presently is the Managing Director of efkairia, LLC, a strategic
consulting small business. He has over 25 years of experience in
academia, government service, Federally Funded Research and
Development Centers, and the private sector, most recently as the
Principal Associate Director for Global Security at Los Alamos
National Laboratory. Dr. Rees is widely recognized internationally
as a scientist, engineer, and a leader in national security, basic
research, and national laboratory policy. For his contributions and
service, he has received numerous national and international
awards.
Dr. Rees was the Deputy Under Secretary of Defense for
Laboratories and Basic Sciences, DUSD (LABS), responsible for
providing scientific leadership, management oversight, policy
guidance, and coordination of the more than $1.8 billion annual
Basic Research programs of the Military Services and Defense
Agencies. In this capacity, he had cognizance over the entire
Defense Basic Research portfolio. In addition, he was responsible
for DoD Science, Technology, Engineering and Mathematics (STEM)
education and workforce issues, grants policy, and international
S&T programs. Dr. Rees was responsible for Defense Laboratories
policy, involving more than 45,000 scientists and engineers.
Prior to joining the DoD, Dr. Rees was a Program Manager for the
CBRNE Countermeasures and the Critical Infrastructure Protection
portfolios at the Homeland Security Advanced Research Projects
Agency, in the Department of Homeland Security Science and
Technology Directorate.
Dr. Rees holds seven patents, has over 120 publications in
archival journals, has edited one book, and has delivered over 300
invited lectures at international meetings, universities, and other
locations. In more than a decade as a Full Professor of Chemistry
and Biochemistry and Materials Science and Engineering at The
Georgia Institute of Technology, he supervised 23 undergraduate
research students, 19 graduate research students, and 20
postdoctoral fellows.
Dr. Rees has earned BS (Texas Tech University) and PhD (UCLA)
degrees in Chemistry and is a Fellow of several national and
international professional societies. He held a postdoctoral
fellowship at MIT and was a Humboldt Research Fellow at Technische
Universitaet, Berlin. Dr. Rees has frequently chaired and served on
national and international scientific committees, panels,
commissions, and task forces. He has been a professional journal
editor and he served on six technical journals' international
advisory boards -- including as a founding board member for
Advanced Materials, the profession's most cited
journal.
Commenting on today's announcement, Jeremy Barbera, Chairman and
CEO of Vantage Health stated, "We are delighted to welcome Dr.
William Rees to the Vantage Health Board. Given the extraordinary
technology and scientific breadth of his government and commercial
industry experience, which recently includes management and
oversight of the $1.8 billion annual Basic Research programs
of the Military Services and Defense Agencies and, earlier in his
career, his experience as Program Manager in the Department of
Homeland Security Science and Technology Directorate, we are
confident that his unique insight and international perspective
will be valuable resources as Vantage Health continues its growth
into a global mobile healthcare technology company."
Dr. Rees stated, "The combination of having set up a new
organization during the formative years of the DHS Science and
Technology Directorate with significant international experience
provides insight and background to assist the Board and Company at
this time. I believe that Vantage Health has identified a
technology with the potential to offer rapid and economical
feedback on diseases of worldwide impact. They are well positioned
to provide diagnostics that will not only make a difference in
people's lives, but will do so cost effectively. I am honored to
join the Board of this innovative company with a product that can
positively influence global health and I look forward to
contributing to Vantage Health's momentum."
About Vantage Health Inc. Vantage Health Inc. -- a leader in
mobile health technology -- is developing personalized and
point-of-care screening using Apps based upon chemical sensing
residing within a small device attached to a smartphone.
With its foundations in advanced nanotechnology, the company's
first product, the Vantage Health Sensor, is the convergence of
nano-electronics, bio-informatics, and wireless technology to
create the next generation mobile health application.
The first mobile App is expected to be for lung cancer screening
with additional mobile healthcare Apps in the planning
stages. The company has offices in Redwood City, CA and New
York. For more information, please visit
http://www.vantagehealthinc.com
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties that could cause
actual results to be materially different from historical results
or from any future results expressed or implied by such
forward-looking statements. Such forward-looking statements
include, among other things statements with respect to our
objectives and strategies to achieve those objectives, as well as
statements with respect to our beliefs, plans, expectations,
anticipations, estimates or intentions. Such forward-looking
statements may also include statements, among other things,
concerning the efficacy, safety and intended utilization of
Vantage's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ
materially include, among others, the risk that product candidates
that appeared promising in early research and clinical trials do
not demonstrate safety and/or efficacy in larger-scale or later
clinical trials, trials may have difficulty enrolling, Vantage may
not obtain approval to market its product candidates, or outside
financing may not be available to meet capital requirements. These
forward-looking statements are based on our current expectations.
We caution that all forward-looking information is inherently
uncertain and actual results may differ materially from the
assumptions, estimates or expectations reflected or contained in
the forward-looking information, and that actual future performance
will be affected by a number of factors, including economic
conditions, technological change, regulatory change and competitive
factors, many of which are beyond our control. Therefore, future
events and results may vary significantly from what we currently
foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company's most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024